Orphan Drugs Market Growth in the United States has Risen Dramatically - Industry Forecast, 2016-2022
Global Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan drugs form a niche yet considerably profitable segment of the pharmaceutical industry. Furthermore, the market exclusivity periods enjoyed by these drugs owing to favorable government legislations especially in the U.S. and Europe add to their value and profitability.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/204
Orphan drugs are specialized pharmaceutical agents that are administered for treatment of rare (orphan) diseases. These diseases have a very low prevalence rate, hence, pharmaceutical companies do not readily invest in these drugs as the returns on investment in orphan drugs is risky when compared with non-orphan drugs. Moreover, multiple clinical trials for drug testing cannot be voluntarily performed due to the small patient population. However, orphan drugs have shown tremendous potential in diagnosis and treatment of cancer, this trend is expected to continue throughout the forecast period. In addition, the increase in indications of orphan drugs to treat an array of different diseases such as lymphoma, leukemia, myeloma, and others boost the market growth.
The major factors that drive the global orphan drugs market are conducive government regulations, market exclusivity for orphan drugs, and surge in prevalence of rare diseases. In addition, growth in novel indications designated for known orphan drugs, and untapped emerging markets thereby provide lucrative opportunities for market growth. However, limited patient pool for clinical trial & product marketing and high treatment costs per patient restrain the market growth.
The oncologic disease type segment occupies the greatest share in the orphan drug market owing to the array of diverse forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population. Whereas, the renal cell carcinoma indication is anticipated to grow at the highest rate. The growth for this segment is due to increase in investment in R&D throughout the world along with surge in awareness about kidney cancer. Multiple myeloma currently dominates the indication segment and is expected to grow at a CAGR of 7.8%.
In 2015, Asia-Pacific and LAMEA collectively accounted for around two-fifths of the global orphan drugs market and are expected to continue this trend due to rise in awareness regarding orphan drugs in China, India, and other developing economies. Various governmental and non-governmental organizations implement favorable legislations that supplement the growth of orphan drugs market. In addition, increase in investment in R&D for drug development by public and private sectors is also expected to boost the market growth.
Table Of Content
Chapter: 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
Chapter: 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS.
3.4.1. Patent analysis by year (2010-2016)
3.4.2. Patent analysis by region
3.4.3. Patent analysis by indication
3.6. MARKET DYNAMICS
184.108.40.206. Favorable government policies
220.127.116.11. Availability of exclusivity for orphan drugs
18.104.22.168. Surge in prevalence of rare diseases
22.214.171.124. Limited patient pool for clinical trials and product marketing
126.96.36.199. High treatment costs per patient
188.8.131.52. Use of orphan drugs for novel conditions/indications
184.108.40.206. Untapped emerging markets
Access Full Summery @ https://www.alliedmarketresearch.com/orphan-drug-market
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Growth in the United States has Risen Dramatically - Industry Forecast, 2016-2022 here
News-ID: 1566411 • Views: 327
More Releases from Allied Market Research
Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market Expected to Reach $7.05 …
According to a new report published by Allied Market Research, titled, “Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market by Product, Age Group, and End User: Opportunity Analysis and Industry Forecast, 2020–2027," the global Diphtheria, Tetanus, and Pertussis Vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% from 2020-2027. The DTaP segment accounted for major
Burn Care Market Expected to Reach $3,134 Million by 2027
According to a new report published by Allied Market Research, titled, “Burn care Market by Product, Depth of Burn, and End User: Opportunity Analysis and Industry Forecast, 2020–2027," the global burn care market size was valued at $1,992 million in 2019, and is projected to reach $3,134 million by 2027, growing at a CAGR of 5.6% from 2020 to 2027. Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4395 Burns are injuries
Drug Delivery Devices Market projected to Cross $26.7 Billion by 2026
Drug Delivery Devices Market size was valued at $19 billion in 2018, and is expected to reach $26.7 billion by 2026, registering a CAGR of 4.3% from 2019 to 2026. Drugs are used to improve health and to extend lives. However, the medications can be taken in various ways, including by swallowing, by absorption, by inhalation, through the skin, and by intravenous injection. For this, the drug delivery devices are developed,
Pharmaceutical Filtration Market on Position to Hit $7.74 Billion by 2026
Pharmaceutical filtration is defined as a filtration process to separate suspended particles from a medium or solution by passing them through a membrane. They reduce or eliminate the bacteria or other microorganisms in process components. The filtration process can be combined with other pharmaceutical manufacturing operations. Pharmaceutical filters are used in the production of small molecule ingredients such as active pharmaceutical ingredients (APIs) and pharmaceutical excipients. In addition, it is
More Releases for Orphan
Protalex receives orphan drug designation for ITP
Protalex, a biopharmaceutical company dedicated to develop orphan drug or therapies for the effective treatment of patients with rare diseases, has recently announced that its novel drug candidate, PRTX 100 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of persistent, chronic immune thrombocytopenia (ITP). PRTX-100 is currently being evaluated in its Phase ½ trial in patients who have previously been treated with
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Europe Orphan Drug Pipeline Analysis 2014
Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term “orphan” was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European Union, orphan drugs are known as orphan medicinal products. Many treatments which are commercially available in today’s world lack the ability to address most
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan